Proof of concept for claudin-targeted drug development

Claudins (CLs) are a family of tetra-integralmembrane proteins that are a key structural and functional component of tight junctions. CLs are overexpressed in somemalignant tumors. Claudin-4 is highly expressed in the epithelial cells covering mucosal immune tissues. CLs may therefore be a potential target for improving drug absorption, treating cancer, and developing mucosal vaccine. Research using Clostridium perfringens enterotoxin has resulted in proofs of concept for CL-targeted drug development. A platform for the creation of CL binders, such as immunization of CL and preparation of CL proteins, is now beginning to be established.